Allowing the producer-dominated market to set drug prices has spiraled the cost of cancer drugs out of control. Drug pricing can be reduced while preserving the profit-making incentive, by linking price to a true measure of quality: preservation and meaningful prolongation of life. Published in the Journal of Clinical Oncology, October 2013.
By Hagop M. Kantarjian, Baker Institute scholar in health policy; Tito Fojo, National Cancer Institute, National Institutes of Health; Michael Mathisen, MD Anderson Cancer Center; and Leonard A. Zwelling, MD Anderson Cancer Center
Oct. 1, 2013, 11:50 a.m.